AU2010290989B2 - CLEC14A inhibitors - Google Patents

CLEC14A inhibitors Download PDF

Info

Publication number
AU2010290989B2
AU2010290989B2 AU2010290989A AU2010290989A AU2010290989B2 AU 2010290989 B2 AU2010290989 B2 AU 2010290989B2 AU 2010290989 A AU2010290989 A AU 2010290989A AU 2010290989 A AU2010290989 A AU 2010290989A AU 2010290989 B2 AU2010290989 B2 AU 2010290989B2
Authority
AU
Australia
Prior art keywords
clec14a
tumour
compound
antibody
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010290989A
Other languages
English (en)
Other versions
AU2010290989A1 (en
Inventor
Roy Bicknell
Manuela Mura
Xiaodong Zhuang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2010290989A1 publication Critical patent/AU2010290989A1/en
Application granted granted Critical
Publication of AU2010290989B2 publication Critical patent/AU2010290989B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010290989A 2009-09-03 2010-09-03 CLEC14A inhibitors Ceased AU2010290989B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23958409P 2009-09-03 2009-09-03
US61/239,584 2009-09-03
PCT/GB2010/001689 WO2011027132A1 (en) 2009-09-03 2010-09-03 Clec14a inhibitors

Publications (2)

Publication Number Publication Date
AU2010290989A1 AU2010290989A1 (en) 2012-03-15
AU2010290989B2 true AU2010290989B2 (en) 2016-05-19

Family

ID=43333027

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010290989A Ceased AU2010290989B2 (en) 2009-09-03 2010-09-03 CLEC14A inhibitors

Country Status (8)

Country Link
US (1) US9255148B2 (https=)
EP (1) EP2473529B1 (https=)
JP (1) JP5962996B2 (https=)
AU (1) AU2010290989B2 (https=)
CA (1) CA2810119C (https=)
ES (1) ES2567030T3 (https=)
HU (1) HUE028878T2 (https=)
WO (1) WO2011027132A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187556A1 (en) * 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
GB201501004D0 (en) * 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
EP3430050A1 (en) * 2016-03-15 2019-01-23 Cancer Research Technology Limited Antibodies and related molecules and uses thereof
CA3015293A1 (en) * 2016-03-15 2017-09-21 Cancer Research Technology Limited Chimeric antigen receptor
CN110312735A (zh) * 2016-09-08 2019-10-08 宇里技术有限公司 特异性地结合至clec14a的去糖基化抗体及其用途
CN113336830B (zh) * 2017-03-17 2023-07-07 浙江孚诺医药股份有限公司 肿瘤靶向多肽、制备方法及其应用
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079492A2 (en) * 2001-02-14 2002-10-10 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030175900A1 (en) * 1999-08-31 2003-09-18 Genentech, Inc. Compositions and methods for the treatment of tumor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030054400A1 (en) 1997-09-17 2003-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
US6894148B2 (en) 1997-11-12 2005-05-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020015950A1 (en) 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
ATE363489T1 (de) 1999-03-08 2007-06-15 Genentech Inc In tumoren vervielfältigte gensequenzen und deren diagnostische verwendungen
US7695959B2 (en) 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
US7498034B2 (en) 2000-11-06 2009-03-03 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
US20040033495A1 (en) * 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2003240495A1 (en) 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
US20060099143A1 (en) 2002-11-20 2006-05-11 Roy Bicknell Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
US8293710B2 (en) 2005-01-03 2012-10-23 Blue Blood Biotech Corp. Method for treating wounds using an EGF-like domain of thrombomodulin
US20060148695A1 (en) 2005-01-03 2006-07-06 National Cheng Kung University Novel angiogenic composition and use thereof
AU2006223579A1 (en) * 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP4832515B2 (ja) * 2005-06-09 2011-12-07 ブルー ブラッド バイオテック コーポレーション 創傷治癒用の組成物及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175900A1 (en) * 1999-08-31 2003-09-18 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2002079492A2 (en) * 2001-02-14 2002-10-10 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Also Published As

Publication number Publication date
EP2473529B1 (en) 2016-02-10
CA2810119A1 (en) 2011-03-10
JP2013503842A (ja) 2013-02-04
EP2473529A1 (en) 2012-07-11
WO2011027132A1 (en) 2011-03-10
CA2810119C (en) 2018-10-23
US20120276000A1 (en) 2012-11-01
AU2010290989A1 (en) 2012-03-15
US9255148B2 (en) 2016-02-09
JP5962996B2 (ja) 2016-08-03
HUE028878T2 (en) 2017-01-30
ES2567030T3 (es) 2016-04-19

Similar Documents

Publication Publication Date Title
JP5750433B2 (ja) 診断および治療のための腫瘍関連抗原の同定
AU2010290989B2 (en) CLEC14A inhibitors
US9150647B2 (en) Biological inhibitors of ROR1 capable of inducing cell death
EP3209696B1 (en) Methods and compositions for diagnosis and treatment of glioblastoma
US11919959B2 (en) Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
UA128387C2 (uk) Антитіло до lag3
WO2009044158A2 (en) Inhibitors and uses
US20140377288A1 (en) Compositions and methods related to dna damage repair
US9555109B2 (en) Method of inhibiting cell proliferation induced by alternatively spliced tissue factor by administering a monoclonal antibody
WO2016092301A1 (en) Vascular targeting
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
KR20220080375A (ko) Cd47에 특이적인 항체 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
GD Licence registered

Name of requester: CHIMERIC THERAPEUTICS LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired